Table 2.
Disease-Modifying Therapy
| DMT Escalation | N | DA |
|---|---|---|
| None to Gilenya | 7 | R |
| None to Tecfidera | 1 | R |
| Aubagio to Ofatumumab | 1 | R |
| Plegridy to Gilenya | 1 | R |
| Tecfidera to Ocrevus | 1 | R |
| Copaxone to Gilenya | 2 | R |
| Copaxone to Ocrevus | 2 | R |
| Betaseron to Gilenya | 1 | R |
| Rebif to Gilenya | 1 | R |
| Non-DMT escalation | ||
| Rebif | 4 | NEDA |
| Tecfidera | 7 | NEDA |
| Gilenya | 2 | NEDA |
| Tysabri | 2 | NEDA |
| Aubagio | 1 | NEDA |
| Plegridy | 2 | NEDA |
| Copaxone | 2 | NEDA |
| None | 2 | NEDA |
| Tysabri to Ocrevus due to positive JCV | 2 | NEDA |
| Tecfidera to Gilenya due to GI | 1 | NEDA |
| Ocrevus | 2 | MRIa |
DMT escalation, newly started or changes of disease-modifying therapy to a more potent level; Non-DMT escalation, no change or changes of disease-modifying therapy within the same potent level; N, number of patients; R, clinical relapses; NEDA, no evidence of disease activities; MRIa, magnetic resonance imaging of new T2 lesions; DA, disease activity; JCV, John Cunningham virus; GI, gastrointestinal side effects.